Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIa study (with combination safety run-in) to assess the safety and efficacy of AZD4547 In Combination with either anastrozole or letrozole versus exemestane alone in ER positive breast cancer patients who are progressing on current treatment with Anastrozole or Letrozole

Next Previous
X
Search
Trial Profile

A phase IIa study (with combination safety run-in) to assess the safety and efficacy of AZD4547 In Combination with either anastrozole or letrozole versus exemestane alone in ER positive breast cancer patients who are progressing on current treatment with Anastrozole or Letrozole

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABSK 091 (Primary) ; Anastrozole; Exemestane; Letrozole
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RADICAL

    • Most Recent Events

    • 17 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 04 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top